CRISPR Therapeutics AG (NASDAQ:CRSP) and Avid Bioservices Inc. (NASDAQ:CDMOP) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics AG 59 0.00 34.37M -0.46 0.00
Avid Bioservices Inc. 27 0.00 42.71M -0.18 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of CRISPR Therapeutics AG and Avid Bioservices Inc.


Table 2 represents CRISPR Therapeutics AG (NASDAQ:CRSP) and Avid Bioservices Inc. (NASDAQ:CDMOP)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics AG 57,959,527.82% -2.6% -2%
Avid Bioservices Inc. 160,082,458.77% 0% 0%

Analyst Recommendations

The Ratings and Recommendations for CRISPR Therapeutics AG and Avid Bioservices Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CRISPR Therapeutics AG 0 0 3 3.00
Avid Bioservices Inc. 0 0 0 0.00

CRISPR Therapeutics AG’s upside potential currently stands at 10.16% and an $72 consensus price target.

Institutional and Insider Ownership

CRISPR Therapeutics AG and Avid Bioservices Inc. has shares owned by institutional investors as follows: 46.8% and 0.72%. Insiders owned 0.4% of CRISPR Therapeutics AG shares. Competitively, insiders own roughly 7.06% of Avid Bioservices Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CRISPR Therapeutics AG 1% 49.37% 59.3% 63.07% 101.48% 153.31%
Avid Bioservices Inc. 0.24% 0.8% -2.15% 2.74% 2.85% 6.44%

For the past year CRISPR Therapeutics AG was more bullish than Avid Bioservices Inc.


On 6 of the 10 factors Avid Bioservices Inc. beats CRISPR Therapeutics AG.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source link